Neogen Corporation’s most recent fiscal year ending May 2026 highlights ongoing investment in research and development centered on proprietary diagnostic test kits and genomics services for food safety and animal health. The company continues to streamline operations, including divesting its Cleaners and Disinfectants business to sharpen focus on core growth areas. With a global footprint spanning over 28 countries and distribution in more than 100, Neogen faces currency exposure and regulatory scrutiny but leverages patented immunoassay technologies and a strong sales network to sustain competitive positioning. Its financial profile shows solid liquidity with a current ratio above 3.8 alongside $800 million of total debt, reflecting active management of leverage and financing costs.